Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by pirateinvestoron May 27, 2022 11:45am
260 Views
Post# 34712286

AZOVA deal was TERMINATED

AZOVA deal was TERMINATEDEXACT COVID-19 Antibody Test The New York State Department of Health (NYSDOH) provided conditional approval to Company’s EXACT COVID-19 Antibody Test. We believe this test is part of the next generation of tools in the fight against COVID-19. The test gives peace of mind because it can detect an immune response in both vaccinated and previously COVID-19 infected people. It also has the potential to give the health care system key insights and data into the relationship between antibody levels and breakthrough infections and reinfections.

The Company further reports that its previously announced marketing agreement with Azova Inc, for it's direct to consumer COVID-19 antibody test has been terminated. This is owing to guidance from the FDA that it is exerting its authority over the home collection of test samples for any product related to COVID-19 and the Company does not have authorization from the FDA for home collection of samples.

The Company is actively pursuing a number of potential customers for the COVID-19 antibody test approved by NYSDOH under CLIA. The market of COVID-19 related products — including antibody testing — remains dynamic and as such difficult to predict. However, we have maintained our ability to react accordingly and continue to streamline our operations to take advantage of a rise of COVID-19 cases in the future.
<< Previous
Bullboard Posts
Next >>